Trial Profile
Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 02 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 13 Jun 2013 Planned end date changed from 1 Mar 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 04 Nov 2011 Planned end date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.